; (4) in subsection (f)— (A) in paragraph (1)(A)(vi), by striking 2023 and inserting 2028 ; and (B) in paragraph (2)(F), by striking 2023 and inserting 2028 ; and (5) in subsection (g), by adding at the end the following new paragraph: (4) Gender-affirming care (A) In general Except as provided in subparagraph (B), the term gender-affirming care means, with respect to an individual, any of the following: (i) Performing any surgery for the purpose of changing the body of such individual to correspond to a sex that differs from their biological sex, including— (I) castration; (II) orchiectomy; (III) scrotoplasty; (IV) vasectomy; (V) hysterectomy; (VI) oophorectomy; (VII) ovariectomy; (VIII) metoidioplasty; (IX) penectomy; (X) phalloplasty; (XI) vaginoplasty; (XII) vaginectomy; (XIII) vulvoplasty; (XIV) reduction thyrochondroplasty; (XV) chondrolaryngoplasty; and (XVI) mastectomy. (ii) Any plastic surgery that feminizes or masculinizes the facial features for the purposes described in clause (i). (iii) Any placement of chest implants to create feminine breasts for the purposes described in clause (i). (iv) Any placement of fat or artificial implants in the gluteal region for the purposes described in clause (i). (v) Administering, supplying, prescribing, dispensing, distributing, or otherwise conveying to an individual medications for the purposes described in clause (i), including— (I) gonadotropin-releasing hormone (GnRH) analogues or other puberty-blocking drugs to stop or delay normal puberty; (II) testosterone or other androgens to biological females at doses that are supraphysiologic to the female sex